UNSPSC 51161823: Althaea

This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B3911G2Q52 and which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 21609 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Rosanae, Order Malvales, Family Malvaceae, and Genus Althaea L., more commonly known as MARSHMALLOW.

UNSPSC 51161823 Althaea is a Commodity code under which state and local governments procure pharmaceutical products and medical supplies, specifically naloxone, over-the-counter medications, and drug deactivation systems for community health and emergency response. Issuing bodies include county health departments and state purchasing alliances managing multi-jurisdiction cooperative contracts. Seminole County, Florida, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, have posted recent solicitations under this code. The work involves sourcing pharmaceutical inventory through established wholesale distribution channels, meeting FDA compliance requirements including current Good Manufacturing Practices and Drug Supply Chain Security Act certification, and managing product availability with specified shelf-life and expiration-date standards.

Recent activity centers in Florida and Minnesota. Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023 (note: date appears erroneous in source). MMCAP posted RFP S1070000015802 on January 20, 2026, establishing multiple-award contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026. Both solicitations require vendors to maintain comprehensive insurance, comply with federal drug-supply regulations, and submit detailed product information including National Drug Codes and manufacturing data. MMCAP's RFP emphasizes pricing competitiveness (75 percent of evaluation weight), administrative fee data format compliance, and EDI capability, with awarded vendors supplying products through authorized wholesalers by July 1, 2026.